Participants 22 65 3
immunotherapy for persistent genital warts.
Participants 326 430 8
recurrent genital warts amenable to destructive therapy, conducted independently in Australia and China.
Participants 439 678 3
Patients received conventional destructive therapy of all evident warts together with intramuscular administration of 1 µg, 5 µg or 25 µg of VLP immunotherapy, or of placebo immunotherapy (0.9% NaCl), as immunotherapy at week 0 and week
Participants 760 931 5
Of 33 protocol compliant Brisbane recipients of placebo immunotherapy, 11 were disease free at two months, and a further 9 demonstrated reduction of > 50% in total wart ar
Participants 1033 1178 6
ng 102 protocol compliant Brisbane recipients of VLP immunotherapy, disease reduction was significantly greater than among the placebo immunother
Participants 1689 1764 4
ed for the 168 Wenzhou protocol compliant subjects who also received VLP im
Participants 1814 1990 4
indings in a previous open label trial that administration of VLP immunotherapy may assist in clearance of recurrent genital warts in patients for whom destructive therapy is u
